Abstract
The HIV-1 integrase (IN) and reverse transcriptase (RT) are essential enzymes in the virus cycle. RT is crucial for the retrotranscription of the RNA viral genome, while IN is involved in the insertion in host chromosome of the proviral double strand DNA produced by RT. This enzyme has two associated functions: the RNA- and DNA-dependent DNA polymerase (RDDP and DDDP) and the ribonuclease H (RNase H). The RNase H function catalyzes the selective hydrolysis of the RNA strand of the RNA:DNA heteroduplex replication intermediate. Since the discovery that catalytic cores of both HIV-1 RNase H and IN are folded in a very similar way, have very similar active site geometries, and show the same DDE triad absolutely required for catalytic activity, some researches were devoted to study IN and RNase H dual inhibitor. Our decennial interest in design and synthesis of IN inhibitors led us to study the activity of our compounds also on RNase H activity. The results of the activities showed by pyrrolyl and quinolonyl diketo acids are reported and discussed.
Keywords: HIV-1, integrase, reverse transcriptase, ribonuclease H, RNase H, RNase H inhibitor, IN inhibitor, dual inhibitors, diketo acids, pyrrole derivatives, quinolinone drivatives
Current Medicinal Chemistry
Title: Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain
Volume: 18 Issue: 22
Author(s): R. Di Santo
Affiliation:
Keywords: HIV-1, integrase, reverse transcriptase, ribonuclease H, RNase H, RNase H inhibitor, IN inhibitor, dual inhibitors, diketo acids, pyrrole derivatives, quinolinone drivatives
Abstract: The HIV-1 integrase (IN) and reverse transcriptase (RT) are essential enzymes in the virus cycle. RT is crucial for the retrotranscription of the RNA viral genome, while IN is involved in the insertion in host chromosome of the proviral double strand DNA produced by RT. This enzyme has two associated functions: the RNA- and DNA-dependent DNA polymerase (RDDP and DDDP) and the ribonuclease H (RNase H). The RNase H function catalyzes the selective hydrolysis of the RNA strand of the RNA:DNA heteroduplex replication intermediate. Since the discovery that catalytic cores of both HIV-1 RNase H and IN are folded in a very similar way, have very similar active site geometries, and show the same DDE triad absolutely required for catalytic activity, some researches were devoted to study IN and RNase H dual inhibitor. Our decennial interest in design and synthesis of IN inhibitors led us to study the activity of our compounds also on RNase H activity. The results of the activities showed by pyrrolyl and quinolonyl diketo acids are reported and discussed.
Export Options
About this article
Cite this article as:
Di Santo R., Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain, Current Medicinal Chemistry 2011; 18 (22) . https://dx.doi.org/10.2174/092986711796504619
DOI https://dx.doi.org/10.2174/092986711796504619 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
Current Drug Metabolism Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Structure-Editing of Nucleic Acids for Selective Targeting of RNA
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Embryonic Signaling Pathways as Potential Targets for the Treatment of Rhabdomyosarcoma)
Current Drug Targets Meet the Guest Editor
Current Genomics Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design Therapeutic Proteins: A to Z
Protein & Peptide Letters Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Oncotargets in Different Renal Cancer Subtypes
Current Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology